Literature DB >> 28681580

Retrospective cytological evaluation of indeterminate thyroid nodules according to the British Thyroid Association 2014 classification and comparison of clinical evaluation and outcomes.

Massimo Giusti1, Barbara Massa2, Margherita Balestra1, Paola Calamaro2, Stefano Gay1, Simone Schiaffino3, Giovanni Turtulici3, Simonetta Zupo4, Eleonora Monti1, Gianluca Ansaldo5.   

Abstract

The cytology of 130 indeterminate nodules (Thy 3) was retrospectively reviewed according to the British Thyroid Association 2014 classification. Nodules were divided into Thy 3a (atypical features) and Thy 3f (follicular lesion) categories. Histology was available as a reference for 97 nodules. Pre-surgical evaluations comprised biochemical tests, color-Doppler ultrasonography (US), semi-quantitative elastography-US (USE), contrast-enhanced US (CEUS), and mutation analysis from cytological slides. Thyroid malignancy was the final diagnosis for 19% of surgically-treated nodules. No statistically significant difference in the risk of malignancy was found between Thy 3a (26%) and Thy 3f (14%) nodules. Histology of the Thy 3a and Thy 3f nodules showed a higher incidence of Hurtle cell adenomas in Thy 3f (29%) than in Thy 3a (3%) nodules (P=0.01). The only pre-surgical difference concerned the BRAF V600E mutation, which was positive in some Thy 3a but not in any Thy 3f nodules (P=0.04). Receiver-operating characteristic (ROC) analysis was used to obtain cut-off values from US (score), USE (ELX 2/1 strain index), and CEUS (time-to-peak index and peak index) data. The cut-off values were similar for Thy 3a and Thy 3f nodules. Data showed that malignancy can be suspected if the US score is >2, ELX 1/2 strain index >1, time-to-peak index >1, and peak index <1. In a sub-group of 24 revised nodules (12 Thy 3a and 12 Thy 3f) with histology as a reference, the diagnostic power of cumulative pre-surgical analysis by means of US, USE, and CEUS showed high positive and negative predictive values (83% and 100%, respectively) for the presence of malignancy in Thy 3a and Thy 3f nodules. In conclusion, in our series of revised Thy 3 nodules, malignancy was low and displayed no significant differences between Thy 3a and Thy 3f categories. The use of cut-offs based on histology as a reference could reduce surgery. Our data support the conviction that, in mutation-negative Thy 3a and Thy 3f nodules, observation should be the first choice when not all instrumental results are suspect.

Entities:  

Keywords:  Indeterminate thyroid nodules; British Thyroid Association 2014 classification; Clinical evaluation; Outcome

Mesh:

Year:  2017        PMID: 28681580      PMCID: PMC5498836          DOI: 10.1631/jzus.B1600075

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  42 in total

1.  Is an Increase in Thyroid Nodule Volume a Risk Factor for Malignancy?

Authors:  Hirotoshi Nakamura; Mitsuyoshi Hirokawa; Hisashi Ota; Minoru Kihara; Akihiro Miya; Akira Miyauchi
Journal:  Thyroid       Date:  2015-05-18       Impact factor: 6.568

2.  The Bethesda System for Reporting Thyroid Cytopathology.

Authors:  Edmund S Cibas; Syed Z Ali
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology.

Authors:  Rohtesh S Mehta; Sally E Carty; N Paul Ohori; Steven P Hodak; Christopher Coyne; Shane O LeBeau; Mitchell E Tublin; Michael T Stang; Jonas T Johnson; Kelly L McCoy; Marina N Nikiforova; Yuri E Nikiforov; Linwah Yip
Journal:  Surgery       Date:  2013-10       Impact factor: 3.982

4.  Examining the Bethesda criteria risk stratification of thyroid nodules.

Authors:  Ahmed Deniwar; Catherine Hambleton; Tina Thethi; Krzysztof Moroz; Emad Kandil
Journal:  Pathol Res Pract       Date:  2015-02-27       Impact factor: 3.250

Review 5.  Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls.

Authors:  M Regina Castro; Hossein Gharib
Journal:  Endocr Pract       Date:  2003 Mar-Apr       Impact factor: 3.443

6.  An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management.

Authors:  Eleonora Horvath; Sergio Majlis; Ricardo Rossi; Carmen Franco; Juan P Niedmann; Alex Castro; Miguel Dominguez
Journal:  J Clin Endocrinol Metab       Date:  2009-03-10       Impact factor: 5.958

7.  Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.

Authors:  Yuri E Nikiforov; Sally E Carty; Simon I Chiosea; Christopher Coyne; Umamaheswar Duvvuri; Robert L Ferris; William E Gooding; Steven P Hodak; Shane O LeBeau; N Paul Ohori; Raja R Seethala; Mitchell E Tublin; Linwah Yip; Marina N Nikiforova
Journal:  Cancer       Date:  2014-09-10       Impact factor: 6.860

8.  The large majority of 1520 patients with indeterminate thyroid nodule at cytology have a favorable outcome, and a clinical risk score has a high negative predictive value for a more cumbersome cancer disease.

Authors:  Teresa Rago; Maria Scutari; Francesco Latrofa; Valeria Loiacono; Paolo Piaggi; Ivo Marchetti; Rossana Romani; Fulvio Basolo; Paolo Miccoli; Massimo Tonacchera; Paolo Vitti
Journal:  J Clin Endocrinol Metab       Date:  2014-04-07       Impact factor: 5.958

9.  Determination of the optimal time interval for repeat evaluation after a benign thyroid nodule aspiration.

Authors:  Eric Nou; Norra Kwong; Lukas K Alexander; Edmund S Cibas; Ellen Marqusee; Erik K Alexander
Journal:  J Clin Endocrinol Metab       Date:  2013-11-25       Impact factor: 5.958

10.  BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer.

Authors:  Eleonora Monti; Michela Bovero; Lorenzo Mortara; Giorgia Pera; Simonetta Zupo; Elena Gugiatti; Mariella Dono; Barbara Massa; Gian Luca Ansaldo; Giusti Massimo
Journal:  Int J Endocrinol       Date:  2015-11-26       Impact factor: 3.257

View more
  6 in total

1.  Role of Strain Elastography and Shear-Wave Elastography in a Multiparametric Clinical Approach to Indeterminate Cytology Thyroid Nodules.

Authors:  Stefano Gay; Simone Schiaffino; Graziana Santamorena; Barbara Massa; Gianluca Ansaldo; Giovanni Turtulici; Massimo Giusti; Thyroid Team At The Policlinico San Martino Genoa
Journal:  Med Sci Monit       Date:  2018-09-08

2.  An H-TERT Mutated Skin Metastasis as First Occurrence in a Case of Follicular Thyroid Carcinoma.

Authors:  Eleonora Monti; Mariella Dono; Edoardo Gonella; Bruno Spina; Francesca Pitto; Floriana Petrogalli; Lucia Conte; Eleonora Ambrosetti; Michele N Minuto; Gian Luca Ansaldo; Silvia Morbelli; Simona Zupo; Massimo Giusti
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-31       Impact factor: 5.555

3.  Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules.

Authors:  Whitney S Goldner; Trevor E Angell; Sallie Lou McAdoo; Joshua Babiarz; Peter M Sadow; Fadi A Nabhan; Christian Nasr; Richard T Kloos
Journal:  Thyroid       Date:  2019-09-27       Impact factor: 6.568

4.  Prevalence of thyroid carcinoma in nodules with thy 3 cytology: the role of preoperative ultrasonography and strain elastography.

Authors:  Giorgos Pikis; Eleni Kandaraki; Demetris Lamnisos; Sereen Abbara; Katerina Kyriakou; Aliki Economides; Panayiotis A Economides
Journal:  Thyroid Res       Date:  2021-04-09

5.  Strain Elastography as a Valuable Diagnosis Tool in Intermediate Cytology (Bethesda III) Thyroid Nodules.

Authors:  Dana Stoian; Florin Borcan; Izabella Petre; Ioana Mozos; Flore Varcus; Viviana Ivan; Andreea Cioca; Adrian Apostol; Cristina Adriana Dehelean
Journal:  Diagnostics (Basel)       Date:  2019-09-13

6.  TIRADS, SRE and SWE in INDETERMINATE thyroid nodule characterization: Which has better diagnostic performance?

Authors:  Ilaria Celletti; Daniele Fresilli; Corrado De Vito; Marco Bononi; Sara Cardaccio; Alessia Cozzolino; Cosimo Durante; Giorgio Grani; Gianmarco Grimaldi; Andrea M Isidori; Carlo Catalano; Vito Cantisani
Journal:  Radiol Med       Date:  2021-06-15       Impact factor: 3.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.